June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Progression of geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration (AMD): five year follow up
Author Affiliations & Notes
  • Nadezhda Cvetkova
    Ophthalmology, University of Regensburg, University of Regensburg, Regensburg, Germany
  • David Maerker
    Ophthalmology, University of Regensburg, University of Regensburg, Regensburg, Germany
  • Horst Helbig
    Ophthalmology, University of Regensburg, University of Regensburg, Regensburg, Germany
  • Footnotes
    Commercial Relationships Nadezhda Cvetkova, None; David Maerker, None; Horst Helbig, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1515. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nadezhda Cvetkova, David Maerker, Horst Helbig, ; Progression of geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration (AMD): five year follow up. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1515.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To determine the area and progression of geographic atrophy in patients with neovascular AMD from 2007 till 2012 using fundus autofluorescence region finder software for OCT Spectralis (Heidelberg Engineering).<br />

 
Methods
 

In this study 73 eyes of 69 patients with neovascular AMD (mean 74 years) were included. We measured the area and progression of geographic atrophy using fundus autofluorescence region finder software for a period of five years. Additionally we investigated the best-corrected visual acuity (BCVA), the number of intavitreal injections and the central retinal thickness measured by optical coherence tomography (OCT Spectralis, Heidelberg Engineering).<br />

 
Results
 

At baseline 52% of study eyes had a single area of geographic atrophy. After five years 71% of study eyes showed geographic atrophy. Mean geographic atrophy size increased from 1.233mm² (SD 1.797) at baseline to 5.094mm² (SD 3.486) after five years of follow up based on quantitative fundus autoflourescence evaluation. On average, the enlargement rate of geographic atrophy per year was 1,170 mm² (range 0,516mm²- 1,994mm²/year). The enlargement rate correlated with the initial area of geographic atrophy (P<0.001). There was a significant correlation between the progression of geographic atrophy and the number of intravitreal injections over five years (P<0.001). In 66 % of study eyes we detected loss of visual acuity, which was associated with a progression of geographic atrophy. There was no statistical significant difference between central retinal thickness measured by OCT at the beginning and after five years of therapy.<br />

 
Conclusions
 

Fundus autoflourescence region finder can be used to visualize and quantify the size and progression of geographic atrophy in patients with neovascular AMD in the daily routine. This study showed a correlation between the initial area of geographic atrophy and the enlargement rate in patients with neovascular AMD. There was a significant correlation between the number of intravitreal injections and the progression of geographic atrophy.<br />

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×